Newsroom

Download PDF Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Sep. 20, 2017– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiNivo study. Under terms of the agreement, EUSA may utilize data from the study for

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 13, 2017– AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in Europe, and a $0.5 million milestone payment from CANbridge related to manufacturing development activities for AV-203, AVEO’s clinical-stage ErbB3 (HER3)

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 5, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 28, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. Tivozanib is indicated for the first line treatment of adult patients with advanced RCC and for adult patients who are vascular endothelial growth factor

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib strategy: a recommendation for approval of tivozanib in advanced renal cell carcinoma (RCC)

Download PDF Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 27, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc. (Hercules) and the sale of common stock via its at-the-market issuance sales agreement with FBR & Co. (FBR). Pursuant to its 2010

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 23, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP’s recommendation is now referred to the European Commission (EC). The EC, which typically

Download PDF – Pre-planned futility analysis of the trial expected midyear 2017;topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has